New Research Highlights the Broader Role of Testosterone in Women’s Health

Quantitatively, testosterone is the most abundant circulating sex steroid in the female body across the entire lifespan, circulating at concentrations up to 20 times higher than estradiol. Shifting the clinical paradigm to prioritize female androgen optimization is foundational to addressing cellular energy deficits, preventing musculoskeletal decay, and providing tissue-protective boundaries against disease.

Key Clinical Takeaways

• The Dominant Female Sex Hormone: The paper exposes a widespread institutional blind spot: by mass and biological activity, women produce significantly more testosterone than estrogen. Labeling testosterone as an exclusively “male” hormone ignores its ubiquitous role in female metabolic, cardiovascular, and neurological function.
• The Anabolic Deficit of Aging: As women transition through perimenopause and menopause, the precipitous decline in testosterone induces an “anabolic deficit.” This systemic depletion is a primary, hidden driver behind rapid bone resorption (osteopenia/osteoporosis), sarcopenia (loss of lean muscle mass), debilitating joint arthralgia, and cognitive decline.
• Mammary Tissue Protection: Dr. DeRosa highlights peer-reviewed data confirming that testosterone acts via the androgen receptor as a natural homeostatic check against estrogen-driven cellular proliferation in human breast tissue, reinforcing its profile as a safe and protective agent rather than a risk factor.
• Subcutaneous Delivery Efficacy: The paper notes that standard oral delivery methods of hormone replacement often fail to optimize active free testosterone because they undergo first-pass liver metabolism and elevate Sex Hormone-Binding Globulin (SHBG). Non-oral, subcutaneous delivery methods bypass this pathway, providing stable, steady-state therapeutic levels directly to peripheral tissues.